• DeutschDeutsch
  • EnglishEnglish
    • ABOUT
    • ONCOLOGY
    • PRODUCT
    • NEWS
    • INQUIRIES
    • VISIT US
ONCOSCIENCE > NEWS

ARCHIVES

  • June 2022
  • May 2022
  • November 2020
  • March 2019
  • October 2018
  • November 2017
  • August 2017
  • April 2016
  • July 2015
  • July 2010
  • October 2009
  • October 2008
  • April 2008
  • October 2007
  • September 2007
  • June 2007
  • September 2005
  • March 2005
  • January 2005
  • October 2004
  • August 2004
  • June 2004
  • March 2004
  • November 2003

SEARCH

  • Oncoscience AG presents results from Phase III study of Nimotuzumab (Theraloc®) in patients with diffuse intrinsic pontine glioma at the 41. SIOP, Sao Paulo, Brazil, October 6th-9th, 2009

    Oncoscience | October 9th, 2009

    On Friday October 9th, 2009 results from the Phase III study of the monoclonal antibody Nimotuzumab were presented. At ...

  • Funcrypta – Poster presentation at European Bioperspectives

    Oncoscience | October 4th, 2008

    Oncoscience AG is a member of the German Funcrypta project. Within the scope of this cooperation a poster will be presen...

  • Oncoscience AG receives EU orphan drug status for the EGFR monoclonal antibody Nimotuzumab (Theraloc®) for the treatment of pancreatic cancer.

    Oncoscience | April 22nd, 2008

    Oncoscience AG announced that their anti-cancer drug Nimotuzumab (Theraloc®) has been designated an orphan drug by the ...

  • The European Medicines Agency, EMEA, concludes its formal validation of the marketing authorization application for Theraloc® (Nimotuzumab) positively

    Oncoscience | October 26th, 2007

    The application for marketing authorization of Theraloc® (Nimotuzumab) was submitted to EMEA on October 4th, 2007. Aft...

  • Oncoscience AG reports marketing authorization approval for Theraloc® (Nimotuzumab) in the Ukraine

    Oncoscience | October 13th, 2007

    On October 12th, 2007 Theraloc® was approved in the Ukraine by the Ministry of Health of Ukraine. As of now Theraloc®...

Posts navigation

Previous 1 2 3
    • LEGAL NOTICE

©Copyright of Oncoscience GmbH 2023

Diese Website benutzt Cookies. Wenn du die Website weiter nutzt, gehen wir von deinem Einverständnis aus.OKDatenschutzerklärung